# Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

> **NCT00062036** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 33 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** interleukin-2 gene
- **BIOLOGICAL:** therapeutic tumor infiltrating lymphocytes
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00062036
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2007-02
- **Final completion:** 2008-09
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00062036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00062036, "Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00062036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*